Oncopeptides AB (LTS:0RN4) Tariff Resilience Score: 0/10 (As of Jul. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RN4 Oncopeptides AB LTS:0RN4
45 GF Score
Price kr1.61
GF Value kr4.41
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Oncopeptides AB Tariff Resilience Score?

Oncopeptides AB has the Tariff Resilience Score of 0, which implies that the company might have .

Oncopeptides AB has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Oncopeptides AB might have .

Oncopeptides AB  (LTS:0RN4) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Oncopeptides AB Tariff Resilience Score Related Terms

LTS:0RN4
45GF Score
Oncopeptides AB LTS:0RN4
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Oncopeptides AB (LTS:0RN4) Overvalued in 2026?

Based on GuruFocus' analysis, Oncopeptides AB stock appears to be undervalued. The current stock price of kr1.61 is trading 63.5% below its estimated GF Value™ of kr4.41. GuruFocus considers Oncopeptides AB to be Possible Value Trap.

Key valuation signals for LTS:0RN4:

  • Tariff Resilience Score: 0
  • GF Value™: kr4.41 vs. price of kr1.61 (63.5% below fair value)
  • GF Score™: 45/100 with 3 warning signs

No single metric tells the full story. See the LTS:0RN4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oncopeptides AB Business Description

Address Luntmakargatan 46, Stockholm, SWE, SE-111 37
Oncopeptides AB is a Swedish biotech company focusing on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Conjugate platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It is a science-driven biotech company developing targeted therapies for hard-to-treat cancers, combining cutting-edge research, entrepreneurial spirit, and a deep commitment to improving patients' lives. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East, Africa, and elsewhere. The company generates maximum revenue from Germany.
45GF Score

Get the complete analysis for LTS:0RN4

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.61
Price
kr4.41
GF Value